CEAPRO INC.
TSX VENTURE : CZO

CEAPRO INC.

September 26, 2005 09:00 ET

Ceapro announces adoption of CeaProve™ in global Glycemic Index study

EDMONTON, Sept. 26 - Ceapro Inc. (TSX VENTURE:CZO) today announced that
its CeaProve™ diabetic test meal has been selected for use in a global
study to develop and test a standardized method for determining the Glycemic
Index of foods.

"This global initiative is important in introducing CeaProve™ to
opinion leaders in the field of diabetes and to those who want to use
CeaProve™ in research and clinical practice for assessing glycemic
responses," said Dr. Mark Redmond, Ceapro's President and CEO. "Each
CeaProve™ diabetic test meal contains exactly 50 grams of available
carbohydrate, in a mixed meal format, which is ideal for use as a research
standard or control."

"We are developing this standardized method of measuring the Glycemic
Index of foods for regulatory purposes," said Dr. Thomas Wolever, University
of Toronto professor and principal investigator for the study. "To assess the
performance of labs around the world, standardized, ready-to-eat foods are
required, and CeaProve™ calibrated wafers are ideal for that purpose."

Labeling of Glycemic Index values on foods has been proposed or is
already occurring in a number of countries, and a number of laboratories are
measuring the Glycemic Index of foods. However, for regulatory purposes, an
approved method is required; standards must be developed to assess the method
and the laboratories using the method. The study will assess the extent and
sources of variation in Glycemic Index values measured by 24 laboratories
around the world.

About CeaProve™

CeaProve™ consists of calibrated wafers made from a proprietary
formulation of proteins, fats, and complex carbohydrates. Each CeaProve™
diabetic test meal contains exactly 50g of available carbohydrate, in a mixed
meal format, which is ideal for use as a research standard or control.
CeaProve™ is also a simple, cost effective, and rapid point-of-care tool to
identify the elevated blood glucose levels indicative of pre-diabetic and
diabetic conditions. The wafers are consumed with a glass of water after an
overnight fast. A quick analysis of the blood, using one of many standard
glucose meters presently on the market, provides an on-the-spot indication of
elevated blood glucose levels. Ceapro is pursuing several strategies to
position CeaProve™ for sale and distribution to the public. These include
selling the product over the counter at Canadian pharmacies and a global
partnership strategy for international markets.

About the Glycemic Index

The Glycemic Index (GI) is a scale that ranks carbohydrate-rich foods by
how much they raise blood glucose levels compared to glucose. A food that is
easily broken down during digestion and quickly absorbed has a high GI value,
whereas a food that is digested and absorbed slowly has a low GI value.
Studies have shown that low GI diets are beneficial for people with diabetes,
and may help lower the risk of developing diabetes, heart disease, cancer, and
the metabolic syndrome. For more information, log on to www.gitesting.com or
www.gilabs.com or www.diabetes.ca.

About Ceapro Inc.

Ceapro Inc., an innovation-driven biotechnology company, develops and
commercializes organic products for medical, cosmetic, and animal health
industries using proprietary technology and natural, renewable resources.
Based in Edmonton, Alberta, Ceapro's shares trade on the TSX Venture Exchange
under the symbol CZO. To learn more about Ceapro, log on to our website at
www.ceapro.com. Shares Outstanding: 36,757,485, Recent Close: $0.28

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or the accuracy of this news release.

This release may contain forward-looking statements. Various factors
could cause actual results to differ materially from those projected in
forward-looking statements. Although the Company believes that the
forward-looking statements contained herein are reasonable, it can give no
assurance that the Company's expectations are correct. All forward-looking
statements are expressly qualified in their entirety by this cautionary
statement.

Contact Information

  • Dr. Mark Redmond, President, Ceapro
    Inc., Telephone: (780) 421-4555; Dr. Thomas Wolever, University of Toronto,
    Telephone: (416) 978-5556